APON(SZ:300753)2021-10-22 16:00Financial Performance - The company's revenue for Q3 2021 was ¥110,426,202.12, representing a slight increase of 0.23% compared to the same period last year[4]. - Net profit attributable to shareholders decreased by 55.70% to ¥11,259,608.92 in Q3 2021, while the year-to-date net profit was ¥48,444,012.81, down 16.85% year-on-year[4]. - The company reported a year-to-date revenue of ¥324,223,345.25, which is a significant increase of 32.56% compared to the same period last year[4]. - Total operating revenue for Q3 2021 reached CNY 324,223,345.25, an increase of 32.5% compared to CNY 244,585,846.88 in the same period last year[24]. - Operating profit for Q3 2021 was CNY 53,850,509.31, down 23.5% from CNY 70,331,195.66 in Q3 2020[24]. - Net profit attributable to shareholders of the parent company was CNY 48,444,012.81, a decrease of 16.8% from CNY 58,257,550.32 in the previous year[25]. - The company reported a basic and diluted earnings per share of CNY 0.3843, down from CNY 0.4622 in the same quarter last year[25]. Assets and Liabilities - The total assets as of the end of Q3 2021 were ¥879,953,288.66, reflecting a growth of 6.37% from the end of the previous year[5]. - Total assets as of the end of Q3 2021 amounted to CNY 879,953,288.66, compared to CNY 827,239,473.77 at the end of Q3 2020[22]. - Total liabilities increased to CNY 98,780,174.08, up from CNY 87,399,278.88 in the previous year[22]. - The total liabilities increased to ¥87,399,278.88 from ¥91,439,428.79 year-on-year[33]. Cash Flow - The company’s cash flow from operating activities showed a negative net amount of ¥18,266,801.30 year-to-date, a decrease of 3.62% compared to the previous year[4]. - Cash flow from operating activities was CNY 313,397,533.98, an increase from CNY 222,022,473.72 in Q3 2020[27]. - The net cash flow from operating activities was -¥18,266,801.30, compared to -¥17,629,439.93 in the same period last year[28]. - Total cash inflow from operating activities was ¥331,728,198.76, an increase from ¥242,153,672.74 year-on-year[28]. - Cash outflow from operating activities totaled ¥349,995,000.06, up from ¥259,783,112.67 in the previous year[28]. - The net cash flow from investing activities was -¥132,496,317.89, compared to -¥143,032,706.25 in the same period last year[28]. - Cash inflow from investing activities was ¥40,835,467.99, down from ¥145,469,884.66 year-on-year[28]. - Cash outflow from investing activities was ¥173,331,785.88, a decrease from ¥288,502,590.91 in the previous year[28]. - The net cash flow from financing activities was -¥34,383,692.18, compared to -¥32,359,286.52 in the same period last year[29]. - The ending balance of cash and cash equivalents was ¥203,423,277.97, down from ¥227,569,960.67 year-on-year[29]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,986[15]. - The largest shareholder, Wang Ningyu, holds 36.15% of shares, amounting to 45,567,811 shares, with 16,291,760 shares pledged[15]. - The company has completed the reduction of 1,859,010 shares, representing 1.77% of the total share capital, by Shanghai Shengyu Heike Venture Capital Center[18]. - The company has committed to not reducing its shareholdings for a period of six months starting from August 6, 2021, reflecting confidence in future business development[17]. Research and Development - Research and development expenses increased by 63.49% to ¥25,761,325.95 for the first nine months of 2021, indicating a focus on innovation[13]. - Research and development expenses for Q3 2021 were CNY 25,761,325.95, compared to CNY 15,757,231.59 in the same period last year, reflecting a 63.5% increase[24]. - The company obtained a medical device registration certificate for a "portable electric infusion pump," enhancing its product offerings in pain management[18]. - The company has received a patent for a "facial expression pain assessment method," marking significant progress in its pain management technology[18]. - The company is focused on expanding its market capabilities through new product development and technological advancements in pain management[18]. Inventory and Goodwill - The company’s inventory rose by 89.70% to ¥60,192,389.60, primarily due to an increase in raw materials and finished goods[10]. - Accounts receivable increased to ¥119,216,112.15 from ¥79,228,290.34 year-over-year[20]. - Inventory levels rose to ¥60,192,389.60 compared to ¥31,729,804.87 at the end of 2020[20]. - The goodwill increased by 104.82% to ¥69,406,058.55, attributed to the acquisition of Baishikang[11]. - The company’s total non-current assets reached CNY 405,523,531.80, up from CNY 303,943,686.01 in the previous year[22]. - The company’s total equity attributable to shareholders of the parent company was CNY 779,499,730.18, an increase from CNY 739,520,007.37 in Q3 2020[22]. - The weighted average return on equity decreased to 1.47% in Q3 2021, down 2.22% from the previous year[4].